Entering text into the input field will update the search result below

CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system

Aug. 17, 2022 7:40 AM ETCytosorbents Corporation (CTSO) StockBy: Ravikash Bakolia, SA News Editor

Business agreement

mediaphotos

  • CytoSorbents (NASDAQ:CTSO) said the Israeli Ministry of Health approved national reimbursement for CytoSorb in certain cardiac surgery indications which is expected to take effect in 2023.
  • The company added that once the policy revision is completed, public hospitals are expected to receive reimbursement for CytoSorb for the particular applications.
  • The company noted that CytoSorb removes a variety of antithrombotic drugs and inflammatory mediators intraoperatively during cardiac surgery. CytoSorb is an extracorporeal blood purification method to reduce excess inflammatory mediators and elevated levels of bilirubin and myoglobin.
  • CTSO +9.84% to $2.01 premarket Aug. 17

Recommended For You

More Trending News

About CTSO Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CTSO--
Cytosorbents Corporation